Skip to main content

FDA Approves Itovebi for Locally Advanced, Metastatic Breast Cancer

By Lori Solomon HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 16, 2024.

via HealthDay

WEDNESDAY, Oct. 16, 2024 -- The U.S. Food and Drug Administration approved Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.

The approval is for the PIK3CA mutation, one of the most commonly mutated genes in HR-positive disease, detected by an FDA-approved test and following recurrence on or after completing adjuvant endocrine therapy.

The approval is based on results of the pivotal phase 3 INAVO120 study. Results from 325 patients showed that the Itovebi-based regimen lowered the risk for disease worsening or death by 57 percent versus palbociclib and fulvestrant alone (15.0 months versus 7.3 months; hazard ratio [HR], 0.43; P < 0.0001) in the first-line setting. At the time of the primary analysis, overall survival data were immature but showed a positive trend (stratified HR, 0.64; P = 0.0338).

“The PI3K pathway plays a pivotal role in disease progression and has been challenging to target,” Komal Jhaveri, M.D., one of the principal investigators of the INAVO120 study, said in a statement. “The Itovebi-based regimen more than doubled progression-free survival and maintained a manageable safety and tolerability profile, adding a new standard in how PIK3CA-mutated breast cancers are treated."

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

AI Support Improves Breast Cancer Detection Accuracy in Mammography

MONDAY, July 14, 2025 -- Artificial intelligence (AI) support improves radiologists' breast cancer detection accuracy when reading mammograms, according to a study published...

Varying Associations ID'd Between Hormone Therapy, Young-Onset Breast Cancer

THURSDAY, July 10, 2025 -- Associations between hormone therapy and young-onset breast cancer (diagnosed at younger than 55 years) vary, according to a study published online in...

Removing Out-of-Pocket Fee Boosts Rates of Digital Breast Mammography

WEDNESDAY, July 9, 2025 -- Removing a modest out-of-pocket fee significantly improves access to digital breast tomosynthesis (DBT; 3D mammography), particularly among underserved...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.